```html

Wegener’s Nasal Granulomatosis

Overview

Wegener’s nasal granulomatosis is a localized form of Granulomatosis with Polyangiitis (GPA), formerly known as Wegener’s granulomatosis. In this variant, the disease primarily involves the nasal cavity, paranasal sinuses, and sometimes the nasopharynx, without widespread organ involvement. The inflammation is characterized by necrotizing granulomas and small‑vessel vasculitis.

• Who it affects: Most patients are adults aged 40–60, with a slight male predominance (approximately 55 % men). However, cases have been reported in adolescents and older adults.
• Prevalence: GPA overall occurs in about 3 cases per 100,000 people worldwide. Isolated nasal granulomatosis represents roughly 10‑15 % of those cases, translating to an estimated 0.3–0.5 cases per 100,000 population.
• Geography: Incidence is similar across North America, Europe, and parts of Asia; slightly higher rates are reported in Scandinavia.

Because the disease may remain confined to the upper airway for months or years, early recognition is essential to prevent progression to systemic GPA, which can affect kidneys, lungs, and other vital organs.

Symptoms

Symptoms arise from chronic inflammation, ulceration, and obstruction of the nasal passages. Most patients experience a combination of the following:

• Persistent nasal congestion – a feeling of blockage that does not improve with typical decongestants.
• Rhinorrhea – clear, mucoid or sometimes bloody discharge.
• Epistaxis (nosebleeds) – frequent or severe bleeding, often from the septum.
• Nasalance/Altered sense of smell (anosmia or hyposmia) – loss or reduction of smell due to mucosal damage.
• Nasal crusting or “boggy” tissue – crusts that are difficult to remove and may bleed when touched.
• Saddle‑nose deformity – collapse of the bridge of the nose from cartilage destruction (seen in chronic disease).
• Facial pain or sinus pressure – often mimics chronic sinusitis.
• Dry mouth or dental problems – secondary to mouth breathing.
• Ear fullness or otitis media – eustachian tube dysfunction from sinus inflammation.
• Hoarseness or sore throat – involvement of the nasopharynx and larynx.
• Systemic signs (less common in isolated nasal disease) – mild fever, fatigue, weight loss, or arthralgias.

Causes and Risk Factors

The exact cause of GPA—including its nasal‑only form—is unknown, but research points to a combination of autoimmune, genetic, and environmental factors.

Autoimmune Mechanism

• Anti‑proteinase 3 antineutrophil cytoplasmic antibodies (PR3‑ANCA, formerly c‑ANCA) are detected in ~70‑80 % of patients with systemic GPA and in a smaller proportion (30‑50 %) of isolated nasal cases.
• These antibodies activate neutrophils, causing them to release enzymes that damage blood vessel walls, leading to necrotizing granulomas.

Genetic Predisposition

• HLA‑DPB1*04:01 and HLA‑DRB1*04 have been linked with increased GPA risk.
• Family clustering is rare but documented, suggesting a modest hereditary component.

Environmental Triggers

• Exposure to silica dust, farming chemicals, and certain infections (e.g., Staphylococcus aureus colonization of the nose) may precipitate disease in susceptible individuals.
• Smoking is a recognized risk factor for more severe disease and relapse.

Who Is at Higher Risk?

• Adults 40–60 years old, especially males.
• People with a history of chronic sinusitis or nasal polyps.
• Individuals with positive PR3‑ANCA or a family history of autoimmune vasculitis.

Diagnosis

Diagnosing Wegener’s nasal granulomatosis requires a systematic approach to differentiate it from common sinus disease, infections, and neoplasms.

Clinical Evaluation

• Detailed history focusing on duration of nasal symptoms, bleeding, crusting, and any systemic complaints.
• Physical examination of the nasal cavity with a nasal speculum or otoscopic camera; look for ulcerations, necrotic tissue, and septal perforation.

Laboratory Tests

• ANCA testing: PR3‑ANCA (c‑ANCA) is the most specific; a positive result supports GPA but is not definitive on its own.
• Complete blood count, renal panel, and urinalysis to screen for hidden systemic involvement.
• Erythrocyte sedimentation rate (ESR) or C‑reactive protein (CRP) – markers of inflammation.

Imaging

• CT of the sinuses: Shows bony destruction, mucosal thickening, and opacification. “Widened ostiomeatal complex” and “saddle‑nose” changes are characteristic.
• MRI: Helpful if there is concern for orbital or intracranial extension.

Biopsy

A tissue sample from the nasal septum or sinus wall is the diagnostic gold standard. Histopathology typically reveals:

• Necrotizing granulomatous inflammation.
• Vasculitis of small‑ to medium‑sized vessels.
• Absence of infectious organisms (special stains for fungi and bacteria are negative).

Diagnostic Criteria

According to the 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology (ACR/EULAR) criteria for GPA, a combination of clinical features, positive PR3‑ANCA, imaging, and histology yields a score ≥5, confirming the diagnosis.

Treatment Options

Therapy aims to control inflammation, prevent relapses, and preserve nasal structure. Treatment is individualized based on disease severity, ANCA status, and patient comorbidities.

Induction Therapy (First 3–6 months)

• Glucocorticoids: Prednisone 1 mg/kg/day (max 60 mg) tapered over several months. Rapid symptom relief is common.
• Immunosuppressive agents:
  • Rituximab (375 mg/m² weekly for 4 weeks) – preferred for PR3‑ANCA‑positive disease and when fertility or cyclophosphamide toxicity is a concern.
  • Cyclophosphamide (intravenous 15 mg/kg every 2–3 weeks) – effective but carries risks of infertility, bladder toxicity, and secondary malignancy.
  • Methotrexate (15–25 mg weekly) or Mycophenolate mofetil (2–3 g/day) – alternative for mild disease or when rapid tapering of steroids is desired.

Maintenance Therapy (After remission)

• Rituximab 500 mg IV every 6 months for 2‑4 years, or
• Azathioprine 2–2.5 mg/kg/day,
• Methotrexate** (if renal function permits) or Mycophenolate** for up to 5 years.

Adjunctive Treatments

• Topical nasal care: Saline irrigations 2–3 times daily, mupirocin ointment for Staphylococcus colonization, and topical steroids (e.g., budesonide spray) to reduce local inflammation.
• Antibiotics: When secondary bacterial sinusitis is documented.
• Surgical debridement: Endoscopic sinus surgery may be required to remove necrotic tissue, improve drainage, and restore nasal airflow. Surgery is performed after disease quiescence to avoid triggering a flare.

Lifestyle & Supportive Measures

• Smoking cessation (reduces relapse risk).
• Vaccinations – influenza, pneumococcal, and COVID‑19; avoid live vaccines while on high‑dose immunosuppression.
• Bone health – calcium, vitamin D, and bisphosphonates if long‑term steroids are used.
• Regular monitoring of blood counts, liver/kidney function, and ANCA titres every 3–6 months.

Living with Wegener’s Nasal Granulomatosis

Effective self‑management helps maintain quality of life and reduces relapse risk.

Daily Nasal Care

• Use isotonic saline spray or neti pot twice daily to keep mucosa moist and clear crusts.
• Apply a thin layer of petroleum‑based ointment (e.g., Aquaphor) after irrigation to prevent drying.
• Avoid nasal picking or aggressive blowing; use a soft tissue and gentle pressure.

Medication Adherence

• Set phone or app reminders for oral meds and infusion appointments.
• Keep a medication log; discuss any side effects promptly with your rheumatologist.

Monitoring & Follow‑up

• Schedule rheumatology visits every 3 months during the first year, then every 6–12 months if stable.
• Report new symptoms such as hematuria, cough, or unexplained fatigue—these may signal systemic spread.

Psychosocial Support

• Join patient support groups (e.g., Vasculitis Foundation forums).
• Consider counseling if facial deformities or chronic illness affect mental health.

Practical Tips

• Humidify indoor air, especially in winter.
• Avoid exposure to dust, chemicals, and strong odors that irritate the nasal passages.
• Stay hydrated; adequate fluid intake keeps secretions thin.

Prevention

Because the exact cause is unknown, primary prevention is limited. However, steps can reduce the likelihood of disease onset or flare:

• Quit smoking and limit exposure to secondhand smoke.
• Minimize occupational exposure to silica, dust, and chemicals; use protective masks when exposure is unavoidable.
• Promptly treat chronic sinus infections and eradicate nasal Staphylococcus aureus colonization (often with mupirocin).
• Maintain up‑to‑date vaccinations to prevent infections that could trigger an immune response.

Complications

If untreated or poorly controlled, Wegener’s nasal granulomatosis can lead to serious sequelae:

• Structural damage: Septal perforation, saddle‑nose deformity, and chronic sinus obstruction.
• Progression to systemic GPA: Kidney involvement (rapidly progressive glomerulonephritis), pulmonary hemorrhage, or necrotizing vasculitis of other organs.
• Secondary infections: Chronic sinusitis, osteomyelitis of the facial bones, or invasive fungal sinus disease (especially in immunosuppressed patients).
• Medication toxicity: Steroid‑induced osteoporosis, cyclophosphamide‑related bladder cancer, or rituximab‑related hypogammaglobulinemia.
• Psychological impact: Reduced quality of life due to facial changes, chronic pain, or medication side effects.

When to Seek Emergency Care

---

Sources: Mayo Clinic, CDC, National Institutes of Health (NIH), World Health Organization (WHO), Cleveland Clinic, “Granulomatosis with Polyangiitis: 2022 ACR/EULAR Classification Criteria” (J Rheumatol 2022), and peer‑reviewed articles from The Lancet Rheumatology and Arthritis & Rheumatology.

```